Description
Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and children who weigh at least 77 pounds (35 kg):
- who have not received any HIV-1 medications and who have less than or equal to 100,000 copies/mL HIV-1 in the blood, or
- to replace their current HIV-1 regimen in those who meet certain requirements per their doctor
Odefsey contains 200 mg of Emtricitabine, 25 mg of Rilpivirine, and 25 mg of Tenofovir alafenamide.
Directions
Take one tablet by mouth once daily with food.
Ingredients
The active ingredients in each tablet include Emtricitabine, Rilpivirine, and Tenofovir-alafenamide.
Contraindications
Do not take Odefsey with drugs that can cause decreases in rilpivirine plasma concentrations.
Cautions
WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B
See full prescribing information for complete boxed warnings.
Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of ODEFSEY. Hepatic function should be monitored closely in these patients. If appropriate, anti-hepatitis B therapy may be warranted. (5.1)
Talk to your doctor about any allergies you may have. Skin and hypersensitivity reactions can occur if you are allergic to Odefsey or any of the ingredients or excipients.
Tell your doctor about any medications you take. Odefsey can interact with certain medications that can cause severe reactions.
Once you are prescribed and buy Odefsey, then it is important to know that Odefsey can cause liver damage. Liver enzymes should be monitored.
Depression or mood changes have been reported with Odefsey treatment. Tell your doctor right away if you experience sadness, hopelessness, anxiety, or suicidal thoughts or ideations.
Odefsey can cause kidney damage or worsen kidney function. Kidney function and labs should be monitored.
Taking Odefsey with other medications that can cause QT prolongation can increase the risk of Torsade de Pointes.
Lactic acidosis or liver enlargement may occur with Odefsey treatment. Your doctor may discontinue Odefsey if you develop symptoms or lab findings of lactic acidosis or liver damage.
Your immune system may change with the use of Odefsey.
Tell your doctor if you are pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed.
Side Effects
The most common side effects of Odefsey include:
These may not be all of the possible side effects, so tell your doctor right away if you experience side effects or if your side effects become bothersome or won't go away.
References:
- Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) Patient Information. Foster City, CA: Gilead Sciences, Inc.; 2021.
- Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) Prescribing Information. Foster City, CA: Gilead Sciences, Inc.; 2021.
About Dr. Savannah Muncy (Page Author)
Dr. Muncy (PharmD) studied science and education as an undergraduate before attending the Appalachian College of Pharmacy where she completed her PharmD in three years. She is currently using her pharmacy and healthcare expertise to write medical content for clients all around the world. She is focused on delivering the most current, accurate, and engaging information to healthcare professionals and patients. Read More....
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 13230